Routine vaccination against MenB Considerations for implementation

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 2, 2014, Pages 310-316

  Kaaijk, Patricia ^a   VanderEnde, Arie ^b   Luytjes, Willem ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Carriage; Epidemiology; Immunogenicity; MenB; Strain variation; Vaccination strategy; Vaccine safety

Indexed keywords

MENINGOCOCCUS VACCINE; 4CMENB VACCINE;

ACTIVE IMMUNIZATION; BACTERIAL STRAIN; COST EFFECTIVENESS ANALYSIS; DISEASE CARRIER; DRUG COST; DRUG RESEARCH; DRUG SAFETY; HEALTH CARE PLANNING; HEALTH PROGRAM; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MENINGOCOCCEMIA; MOLECULAR TYPING; NEISSERIA MENINGITIDIS; NONHUMAN; REVIEW; ADOLESCENT; CHILD; EPIDEMIOLOGICAL MONITORING; FEMALE; HEALTH; IMMUNOLOGY; INFANT; MALE; MENINGITIS, MENINGOCOCCAL; NEWBORN; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; PROCEDURES; VACCINATION; YOUNG ADULT;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGICAL MONITORING; FEMALE; GLOBAL HEALTH; HUMANS; INFANT; INFANT, NEWBORN; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINATION; YOUNG ADULT;

EID: 84895819551     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.26816     Document Type: Review

References (48)

1. Granoff DM, Harrison LH, Borrow R. Vaccines, 5th Ed. Philadelpia: Saunders Elsevier, 2008.
2. Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011; 11:969-85; PMID:21615224; http://dx.doi.org /10.1517/14712598.2011.585965
3. Xie O, Pollard AJ, Mueller JE, Norheim G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine 2013; 31:2852- 61; PMID:23623866; http://dx.doi.org/10.1016/j. vaccine.2013.04.036
4. Trotter CL, Gay NJ, Edmunds WJ. The natural history of meningococcal carriage and disease. Epidemiol Infect 2006; 134:556-66; PMID:16238823; http://dx.doi.org/10.1017/S0950268805005339
5. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Neisseria meningitidis, 2011. Available via the Internet: http://wwwcdcgov/ abcs /reports-f indings /survreports /mening11pdf 2012.
6. Health Protection Agency. Invasive meningococcal infections (England and Wales), annual report for 2011/12. Health Prof Rep 2013; 7:32-4
7. Netherlands Reference Laboratory for Bacterial Meningitis. Bacterial Meningitis in the Netherlands. Annual report 2010. Available via the Internet: http://wwwamcnl/web/Research/Departments/Overview/ Medical-Microbiology/Medical- Microbiology/ Current-research-1htm 2011.
8. Steindl G, Liu YL, Schmid D, Orendi U, Kormann- Klement A, Heuberger S. Epidemiology of invasive meningococcal disease in Austria 2010. Wien Klin Wochenschr 2011; 123(Suppl 1):10- 4; PMID:21935643; http://dx.doi.org/10.1007/ s00508-011-0058-0
9. Health Protection Surveillance Centre Ireland. Quarterly report on invasive meningococcal disease, bacterial and viral meningitis in Ireland. Available via the Internet: http://wwwhpscie/hpsc/A-Z/VaccinePreventable/ BacerialMeningitis/Publications/QuarterlyReports/ 2012ReportsonBacterialMeningitisInvasiveMeningococcalDisease/File,13938, enpdf2012; Quarter 4.
10. Portero RC, Estepa MG. [Meningococcal disease in Spain: Analysis of the 2009-2010 season]. Boletin epidemiologica semanal 2011; Available via the Internet: http://revista.isciii.es/ public/journals/1/pdf-92.pdf.
11. Skoczynska A, Kuch A, Wasko I, Golebiewska A, Ronkiewicz P. M. M, et al. Surveillance of invasive meningococcal disease in Poland in 2010 11th EMGM Congress 2011 in Ljubljana, Slovenia 2011; Abstract P001:35.
12. Granoff DM. Review of meningococcal group B vaccines. Clin Infect Dis 2010; 50(Suppl 2):S54-65; PMID:20144017; http://dx.doi.org/10.1086/648966
13. Institut für Hygiene und Mikrobiologie Würzburg. Data from the German Reference Center for meningococci in 2012. Available via the Internet: http://wwwmeningococcusuni-wuerzburgde/startseite/ berichte/daten-2012/ 2012.
14. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91; PMID:20001736; http://dx.doi. org/10.1086/649209
15. Dang V, Jamieson FB, Wilson S, Rawte P, Crowcroft NS, Johnson K, Tsang RS, Deeks SL. Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010. BMC Infect Dis 2012; 12:202; PMID:22928839; http://dx.doi. org/10.1186/1471-2334-12-202
16. Gilca R, Deceuninck G, Lefebvre B, Tsang R, Amini R, Gilca V, Douville-Fradet M, Markowski F, De Wals P. The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains. PLoS One 2012; 7:e50659; PMID:23209803; http://dx.doi. org/10.1371/journal.pone.0050659
17. Lahra MM, Enriquez RP. Annual report of the Australian Meningococcal Surveillance Programme, 2011. Commun Dis Intell Q Rep 2012; 36:E251-62; PMID:23186236
18. Health Intelligence Team of the Institute of Environmental Science and Research Limited. The epidemiology of meningococcal disease in New Zealand. Surveillance report 2012; Available via the Internet: http://www.surv.esr.cri. nz/PDF-surveillance/ MeningococcalDisease/2012/2012Annual Rpt.pdf.
19. Gorringe AR, Pajón R. Bexsero: a multicomponent vaccine for prevention of meningococcal disease. Hum Vaccin Immunother 2012; 8:174-83; PMID:22426368; http://dx.doi.org/10.4161/ hv.18500
20. Arnold R, Galloway Y, McNicholas A, O'Hallahan J. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Vaccine 2011; 29:7100-6; PMID:21803101; http://dx.doi. org/10.1016/j.vaccine.2011.06. 120
21. van Alphen L, van den Dobbelsteen G. Meningococcal B vaccine development and evaluation of efficacy. Hum Vaccin 2008; 4:158-61; PMID:18388494; http://dx.doi.org/10.4161/hv.4.2.4871 (Pubitemid 351881185)
22. Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983; 2:355-7; PMID:6135869; http://dx.doi.org/10.1016/S0140-6736(83)90340-9 (Pubitemid 13028927)
23. Sandbu S, Feiring B, Oster P, Helland OS, Bakke HS, Naess LM, Aase A, Aaberge IS, Kristoffersen AC, Rydland KM, et al. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines. Clin Vaccine Immunol 2007; 14:1062-9; PMID:17634513; http://dx.doi. org/10.1128/CVI.00094-07 (Pubitemid 47518071)
24. Boutriau D, Poolman J, Borrow R, Findlow J, Domingo JD, Puig-Barbera J, Baldó JM, Planelles V, Jubert A, Colomer J, et al. Immunogenicity and safety of three doses of a bivalent (B:4:p1.19, 15 and B:4:p1.7-2, 4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin Vaccine Immunol 2007; 14:65-73; PMID:17065257; http://dx.doi.org/10.1128/CVI. 00230-06
25. de Kleijn ED, de Groot R, Labadie J, Lafeber AB, van den Dobbelsteen G, van Alphen L, van Dijken H, Kuipers B, van Omme GW, Wala M, et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 2000; 18:1456- 66; PMID:10618543; http://dx.doi.org/10.1016/ S0264-410X(99)00423-5 (Pubitemid 30017826)
26. van den Dobbelsteen GP, van Dijken HH, Pillai S, van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 2007; 25:2491- 6; PMID:17023098; http://dx.doi.org/10.1016/j. vaccine.2006.09.025 (Pubitemid 46366130)
27. Kaaijk P, van Straaten I, van de Waterbeemd B, Boot EP, Levels LM, van Dijken HH, van den Dobbelsteen GP. Preclinical safety and immunogenicity evaluation of a nonavalent PorA native outer membrane vesicle vaccine against serogroup B meningococcal disease. Vaccine 2013; 31:1065-71; PMID:23273968; http://dx.doi.org/10.1016/j.vaccine.2012.12.031
28. Gorringe AR, Taylor S, Brookes C, Matheson M, Finney M, Kerr M, Hudson M, Findlow J, Borrow R, Andrews N, et al. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles. Clin Vaccine Immunol 2009; 16:1113- 20; PMID:19553555; http://dx.doi.org/10.1128/ CVI.00118-09
29. Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, Burden RE, Miller LB, Moon JE, Bowden RA, Cummings JF, et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011; 29:1413-20; PMID:21199704; http://dx.doi. org/10.1016/j.vaccine.2010.12.039
30. Nissen MD, Marshall HS, Richmond PC, Jiang Q, Harris SL, Jones TR, Jansen KU, Perez JL. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J 2013; 32:364-71; PMID:23114369; http://dx.doi. org/10.1097/INF.0b013e31827b0d24
31. Muzzi A, Mora M, Pizza M, Rappuoli R, Donati C. Conservation of meningococcal antigens in the genus Neisseria. MBio 2013; 4:e00163-13; PMID:23760461; http://dx.doi.org/10.1128/ mBio.00163-13
32. Bettinger JA, Deeks SL, Halperin SA, Tsang R, Scheifele DW. Controlling serogroup B invasive meningococcal disease: the Canadian perspective. Expert Rev Vaccines 2013; 12:505-17; PMID:23659299; http://dx.doi.org/10.1586/ erv.13.30
33. Jolley KA, Brehony C, Maiden MC. Molecular typing of meningococci: recommendations for target choice and nomenclature. FEMS Microbiol Rev 2007; 31:89-96; PMID:17168996; http://dx.doi. org/10.1111/j.1574-6976.2006.00057.x (Pubitemid 46058824)
34. Vogel U. European efforts to harmonize typing of meningococci. Int J Med Microbiol 2011; 301:659- 62; PMID:21992745; http://dx.doi.org/10.1016/j. ijmm.2011.09.001
35. Hao W, Ma JH, Warren K, Tsang RS, Low DE, Jamieson FB, Alexander DC. Extensive genomic variation within clonal complexes of Neisseria meningitidis. Genome Biol Evol 2011; 3:1406-18; PMID:22084315; http://dx.doi.org/10.1093/gbe/ evr119
36. Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A 2010; 107:19490- 5; PMID:20962280; http://dx.doi.org/10.1073/ pnas.1013758107
37. Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet 2013; 381:825-35; PMID:23324563; http://dx.doi.org/10.1016/S0140-6736(12)61961-8
38. Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, et al.; European MenB Vaccine Study Group. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307:573- 82; PMID:22318278; http://dx.doi.org/10.1001/ jama.2012.85
39. Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, Toneatto D, Graña G, Wang H, Clemens R, et al.; V72P10 Meningococcal B Adolescent Vaccine Study group. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379:617- 24; PMID:22260988; http://dx.doi.org/10.1016/ S0140-6736(11)61713-3
40. Prymula R, Esposito S, Kittel C, Kohl I, Toneatto D. P. D. Prophylactic paracetamol in infants decreases fever following concomitant administration of an investigational meningococcal serogroup B vaccine with routine immunizations. 29th Annual Meeting of the European Society for Paediatric Infectious Diseases; The Hague, Netherlands; June 7-11, 2011 Available via internet: http://www.kenes.com/ espid2011/cd/PDF/O219.pdf?zoom-highlightsub=p rymula#search="prymula
41. Snape MD, Philip J, John TM, Robinson H, Kelly S, Gossger N, Yu LM, Kittel C, Toneatto D, Dull PM, et al. Bactericidal Antibody Persistence 2 Years After Immunization With 2 Investigational Serogroup B Meningococcal Vaccines at 6, 8 and 12 Months and Immunogenicity of Preschool Booster Doses: A Follow-on Study to a Randomized Clinical Trial. Pediatr Infect Dis J 2013; 32:1116- 21; PMID:23958808; http://dx.doi.org/10.1097/ INF.0b013e31829cfff2
42. Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 2004; 53:821-32; PMID:15314188; http://dx.doi. org/10.1099/jmm.0.45529-0 (Pubitemid 39238387)
43. Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol Rev 2007; 31:52-63; PMID:17233635; http://dx.doi. org/10.1111/j.1574-6976.2006.00052.x (Pubitemid 46058820)
44. Bogaert D, Hermans PW, Boelens H, Sluijter M, Luijendijk A, Rumke HC, Koppen S, van Belkum A, de Groot R, Verbrugh HA. Epidemiology of nasopharyngeal carriage of Neisseria meningitidis in healthy Dutch children. Clin Infect Dis 2005; 40:899-902; PMID:15736029; http://dx.doi.org/10.1086/428351 (Pubitemid 40365516)
45. Jones GR, Christodoulides M, Brooks JL, Miller AR, Cartwright KA, Heckels JE. Dynamics of carriage of Neisseria meningitidis in a group of military recruits: subtype stability and specificity of the immune response following colonization. J Infect Dis 1998; 178:451-9; PMID:9697726; http://dx.doi. org/10.1086/515622 (Pubitemid 28347928)
46. Read R, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, et al. Impact of a quadrivalent conjugate (MenACWY-CRM) or a serogroup B (4CMenB) meningococcal vaccine on meningococcal carriage in English university students Presentation at the 20th European Monitoring Group on Meningococcies (EMGM); Bad Loipersdorf, Austria; Sept 17-19, 2013
47. Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: an economic and mathematical modelling study of potential impact. Vaccine 2013; 31:2638-46; PMID:23566946; http://dx.doi. org/10.1016/j.vaccine.2013.03.034
48. Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelsteen GP, Postma MJ. Costeffectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence. Hum Vaccin Immunother 2013; 9:1129- 38; PMID:23406816; http://dx.doi.org/10.4161/ hv.23888